Pfizer CEO assessments constructive for COVID for a second time By Reuters

(Reuters) -Pfizer Inc Chief Government Officer Albert Bourla stated on Saturday he had examined constructive for COVID-19.

“I’m feeling properly and symptom free,” Bourla stated in an announcement.

Bourla, 60, again in August had contacted COVID and had began a course of the corporate’s oral COVID-19 antiviral therapy, Paxlovid.

Paxlovid is an antiviral medicine that’s used to deal with high-risk folks, equivalent to older sufferers.

Bourla has obtained 4 doses of the COVID vaccine developed by Pfizer (NYSE:) and its German companion BioNTech.

The chief government stated he has not but taken the brand new bivalent booster.

Developed by Moderna (NASDAQ:) and the crew of Pfizer and BioNTech, the brand new so-called bivalent photographs purpose to deal with the BA.5 and BA.4 Omicron subvariants, which make up 84.8% and 1.8%, respectively, of all circulating variants in the US, based mostly on newest knowledge.

“I’ve not had the brand new bivalent booster but, as I used to be following CDC tips to attend three months since my earlier COVID case which was again in mid-August,” Bourla added.

In August, the FDA licensed Pfizer and Moderna’s up to date booster photographs that focus on the dominant BA.4 and BA.5 Omicron subvariants.

A federal well being company stated this week that over 25 million doses of the so-called bivalent photographs had been despatched out. That consisted of principally the Pfizer/BioNTech vaccine, as manufacturing of the Moderna vaccine ramps up.